GlassScriptPhysician profile
Alan H Boyar
NPI 1295728038
$1,503.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $16.59 · 2021: $56.64 · 2022: $317.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $269.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $231.40 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $146.59 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $117.92 | 2019 | |
| Novo Nordisk INC | $117.41 | 2022 | |
| Pfizer INC. | $99.04 | 2019 | |
| Csl Behring | $91.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $78.08 | 2019-2020 | |
| Shire North American Group INC | $48.04 | 2019 | |
| Genzyme Corporation | $24.90 | 2019 | |
| Hologic Sales and Service, LLC | $23.27 | 2022 | |
| Kaleo, INC. | $22.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.74 | 2019 | |
| Optinose US, INC. | $19.42 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $18.88 | 2022 | |
| Organon LLC | $18.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.47 | 2019 | |
| Abbvie INC. | $13.10 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Boyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.